RxDoctor Payments Data

Gary Deutsch, MD

Internal Medicine · Santa Paula, CANPI 1932194289

Payments from drug & device makers

$612in general payments, 2019–2025

Across 32 payments — averaging $19.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$168
  • Sanofi-aventis U.S. LLC$96
  • Boehringer Ingelheim$90
  • Novo Nordisk$71
  • AstraZeneca$68
  • Pfizer$31
  • plus $88 from 5 others

What the payments were for

  • Food & beverage$612100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$612 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$142,135
Medicare patients
225
Services billed
1,636

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban126$105,512
MounjaroTirzepatide44$44,689
JardianceEmpagliflozin49$41,263
OzempicSemaglutide34$30,629
XareltoRivaroxaban24$27,020
MyrbetriqMirabegron29$19,914
FarxigaDapagliflozin Propanediol14$14,878
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$12,688
JanuviaSitagliptin Phosphate15$12,153
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,292
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$7,112
Gabapentin371$6,345
Losartan Potassium513$5,663
Levothyroxine Sodium370$5,344
Tolterodine Tartrate ErTolterodine Tartrate42$4,352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$105,512126 claims
Lilly USA, LLCMounjaro$16$44,68944 claims
Boehringer IngelheimJardiance$90$41,26349 claims
Novo NordiskOzempic$71$30,62934 claims
Johnson & JohnsonXarelto$16$27,02024 claims
GSKTrelegy Ellipta, Anoro Ellipta$16$16,40429 claims
AstraZenecaFarxiga$68$14,87814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Santa Paula

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →